Protocol summary

Study aim
to evaluate the preventive efficacy of dried lime preparation in common cold among Iranian pilgrims in a randomized, double-blind placebo-controlled clinical trial during Hajj period
Design
In this research, 112 eligible patients were chosen purposefully and were randomly divided into two groups of control and intervention. Group allocation was concealed by assigning a unique code to each participants.
Settings and conduct
Since travel of the Iranian pilgrims to Saudi Arabia last four weeks (two weeks in the city of Mecca and two weeks in the city of Medina), our study was conducted by the present time of pilgrims in these cities. General practitioner visited all patients and enrolled in the trial based on inclusion criteria. Group allocation was concealed by assigning a unique code to each participant. In this study, the participants, the general practitioner who visited the patients, the data collection authorities, those who evaluate the outcome, those who prepare the draft article, and Data Saftey and Monitoring Committee to assign study groups Were blind. But the main investigator was not blind to the study groups.
Participants/Inclusion and exclusion criteria
inclusion criteria: All men and women aged 35 to 80 years participating in the Hajj who agree with the aim of the study exclusion criteria: participants who have asthma participants who have a chronic obstructive pulmonary disease participants who have uncontrolled heart diseases participants who have heart failure participants who have a hepatic and renal failure participants who have a history of previous chest surgery.
Intervention groups
Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried fruit of Citrus aurantifulia was purchased from the green market in Shiraz (Iran) and was authenticated by a botanist and was kept at the Herbarium of the Faculty of Pharmacy, Shiraz University of Medicinal Sciences, Shiraz, Iran. 500 milligram of the milled powder of dried fruit of Citrus aurantifulia and 50 milligrams of sugar as filler filled into a capsule. Control group: In the placebo group, patients received placebo capsules with the same method.(a single dose per day for four weak) Placebo capsule, consisting of 550 milligrams of flour with identical size and shape to test drug.
Main outcome variables
the severity of a cough, rhinorrhea, fever, and body pain that ranged from 0-5 scores (without manifestation to severe symptom).

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20170704034897N2
Registration date: 2018-01-30, 1396/11/10
Registration timing: retrospective

Last update: 2018-01-30, 1396/11/10
Update count: 0
Registration date
2018-01-30, 1396/11/10
Registrant information
Name
Seyed Hossein Owji
Name of organization / entity
Shiraz University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 71 3624 7985
Email address
owji_h@sums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2014-09-10, 1393/06/19
Expected recruitment end date
2014-09-20, 1393/06/29
Actual recruitment start date
2014-09-10, 1393/06/19
Actual recruitment end date
2014-09-20, 1393/06/29
Trial completion date
empty
Scientific title
Preventive efficacy of dried lime (Citrus aurantifulia) in common cold among Hajj pilgrims: A randomized, double-blind placebo-controlled clinical trial
Public title
Efficacy of dried lime in common cold among Hajj pilgrims
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
All men and women aged 35 to 80 years participating in the Hajj who agree with the aim of the study
Exclusion criteria:
participants who have asthma participants who have a chronic obstructive pulmonary disease participants who have uncontrolled heart diseases participants who have heart failure participants who have a hepatic and renal failure participants who have a history of previous chest surgery.
Age
From 35 years old to 80 years old
Gender
Both
Phase
N/A
Groups that have been masked
  • Participant
  • Care provider
  • Outcome assessor
  • Data analyser
  • Data and Safety Monitoring Board
Sample size
Target sample size: 126
Actual sample size reached: 112
Randomization (investigator's opinion)
Randomized
Randomization description
One hundred and twelve eligible patients were randomized into two parallel groups. A statistician generated a randomized list by using NCSS (statistical software) with simple block randomization method. All patients visited by a general practitioner and enrolled participants in the trial were assigned to drug or placebo group, according to randomization list.
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, the participants, the general practitioner who visited the patients, the data collection authorities, those who evaluate the outcome, and Data Saftey and Monitoring Committee to assign study groups Were blind. But the main investigator was not blind to the study groups. Also, the author of the article had been blind at the end of the work too.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Shiraz University of medical sciences
Street address
Shiraz University of medical sciences, Zand street, Shiraz
City
Shiraz
Province
Fars
Postal code
7134814336
Approval date
2014-05-01, 1393/02/11
Ethics committee reference number
EC2798

Health conditions studied

1

Description of health condition studied
common cold
ICD-10 code
J00
ICD-10 code description
Acute nasopharyngitis [common cold]

Primary outcomes

1

Description
the severity of a cough
Timepoint
First , second, third and fourth week after intervention
Method of measurement
By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms)

2

Description
the severity of rhinorrhea
Timepoint
First , second, third and fourth week after intervention
Method of measurement
By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms)

3

Description
the severity of fever
Timepoint
First , second, third and fourth week after intervention
Method of measurement
By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms)

4

Description
the severity of body pain
Timepoint
First , second, third and fourth week after intervention
Method of measurement
By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms)

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried fruit of Citrus aurantifulia was purchased from the green market in Shiraz (Iran) and was authenticated by a botanist and was kept at the Herbarium of the Faculty of Pharmacy, Shiraz University of Medicinal Sciences, Shiraz, Iran. 500 milligram of the milled powder of dried fruit of Citrus aurantifulia and 50 milligrams of sugar as filler filled into a capsule.
Category
Treatment - Drugs

2

Description
Control group: In the placebo group, patients received placebo capsules with the same method.(a single dose per day for four weak) Placebo capsule, consisting of 550 milligrams of flour with identical size and shape to test drug.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Iranian Hajj and Pilgrimage Medical Center in Mecca and Medina
Full name of responsible person
Dr. Mehdi Pasalr
Street address
Shiraz Medical School, Imam Hossein Square, Shiraz, Iran
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
+98 71 3233 8476
Email
pasalar@sums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Seyed Basir Hashemi
Street address
Shiraz University of medical sciences, Zand street, Shiraz
City
Shiraz
Province
Fars
Postal code
7134814336
Phone
+98 71 3230 5410
Email
hashemib@yahoo.com
Web page address
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shiraz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Seyed Hossein Owji
Position
Medical Student
Latest degree
A Level or less
Other areas of specialty/work
Internal Medicine
Street address
Shiraz Medical School, Imam Hossein Square, Shiraz, Iran
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
+98 71 3212 2970
Fax
Email
owji_h@sums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Mehdi Pasalar
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Shiraz Medical School, Imam Hossein Square, Shiraz, Iran
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
+98 71 3233 8476
Fax
Email
pasalar@sums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Seyed Hossein Owji
Position
Medical Student
Latest degree
A Level or less
Other areas of specialty/work
Internal Medicine
Street address
Shiraz Medical School, Imam Hossein Square, Shiraz, Iran
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
+98 71 3212 2970
Fax
Email
owji_h@sums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
Part of the individual information of the participants, such as information on the main outcome of the data in the study, is the possibility of sharing. This information includes some of the demographic characteristics and data related to the severity of a cough, rhinorrhea, body pain and fever.
When the data will become available and for how long
Start the access period 6 months after publishing the results for 1 month
To whom data/document is available
Only for researchers working in academic and scientific institutions
Under which criteria data/document could be used
Only a descriptive survey of data is allowed.
From where data/document is obtainable
By sending an email to the scientific responsible of the study, Dr. Pasalar, at the following address: pasalar@sums.ac.ir
What processes are involved for a request to access data/document
After the request has been sent, it will be answered within a maximum of 2 months.
Comments
Loading...